Although B7H3-targeted therapy is designed to stimulate immune response against tumor cells, therapies that recruit inhibitory molecules like Fas ligand (Fas-L), transforming growth factor beta (TGF-β) and prostaglandin E2 (PGE2) may decrease the cytotoxicity by altering the immunosuppressive tumor microenvironment [9]. The gene discussed is CD276; the disease is neoplasm.